TrialArthritis research & therapy2021

Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.

Yoshiya Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.